Bicycle Therapeutics (BCYC) Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists in Journal for ImmunoTherapy of Cancer

Go back to Bicycle Therapeutics (BCYC) Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists in Journal for ImmunoTherapy of Cancer

Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

January 26, 2021 7:20 AM EST

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that an article highlighting preclinical studies of Bicycles novel, fully synthetic Bicycle systemic immune cell agonists and tumor-targeted immune cell... More